Taiwan Liposome Company, Ltd.

Chairman: Dr. Keelung Hong
Date of Foundation: 1997/11/10
Tel: 886-2-2655-7377 
Fax: 886-2-2655-7366 
Address: 2F, No.3, Yuanqu Street, Nangang Dist., Taipei, Taiwan  
          Website: http://www.tlcbio.com/


Company Description:

Taiwan Liposome Company (TLC) is a specialty biopharmaceutical company focused on research, development, and commercialization of products based on its proprietary drug delivery technologies to improve treatments of cancer, peripheral arterial disease (PAD), age-related macular degeneration (AMD) and infectious diseases. Our strength is optimizing pharmacokinetics with lipid-based nanoparticles formulations to improve efficacy and reduce toxicity.

TLC primarily focuses on two areas of business: Lifecycle management and NCE development. TLC’s proprietary drug delivery and formulation technology has enabled the company to apply those technologies on existing drugs by improving their current therapeutic index and/or reducing side effects, to thus extend their lifecycle by turning them into “New Formulation” drugs.

In the area of NCE development, by using proprietary lipid-based formulation platforms, TLC is able to effectively find formulation strategies for compounds inadequately soluble in water or to decrease toxicity. TLC has already proven its ability through the development of Lipotecan, which was developed from compound zero through to lead compound and scale up, all the way to US IND in just two years. In 2010, Lipotecan was granted Orphan Drug Designation for the treatment of hepatocellular carcinoma (HCC) by both the European Commission and US FDA, it was also accepted into "Green Path" by the Chinese State Food and Drug Administration (CFDA) in 2013.

Since its inception in 1997, TLC has received several important awards and government grants. It was chosen among Red Herring Asia top 100 private companies in 2006, and shortlisted for Red Herring Global 100 in 2007.

Development status:






Age-related macular degeneration

Sustained release reducing the frequency of administration

Phase I/II


RCC, HCC (Orphan Drug designation granted by EMA and US FDA)

Reduced toxicity, synergistic therapeutic efficacy with RT

Phase II



Sustained release of a constant amount of local anesthetic.




Sustained release of corticosteroid. Its lipid formulation allows for injection with 30 gauge needles, extending the applicable disease sites to small joints, and reduce the risk of infection by minimizing the wound size at the applied area.



Non-Hodgkin lymphoma

Effectively reduce the toxicity of existing Vinorelbine drugs, improving efficacy and extends indications.